Building cell therapy leadership in Europe

In these videos, Markwin Velders and Louis van de Wiel of Kite, a Gilead Company, provide a behind the scenes insight into the company’s European operations, including building a new manufactur

Delivering innovative therapies with close industry-NHS part...

It was a crucial moment when NHS England and the National Institute for Health and Care Excellence (NICE)

Immunicum shares fall despite “fantastic” kidney cancer data

Celgene strikes $1.5bn cell therapy deal with Immatics

Bayer boosts cell therapy pipeline with BlueRock acquisition

Bayer has announced it is fully acquiring US cell therapy biotech BlueRock Therapeutics, whose cell therapy pipeline includes a treatment for Parkinson’s disease.

Finding the right reimbursement model for gene therapies

With cell and gene therapies growing more and more important to healthcare, we sat down with Debbie Warner, vice president of Kantar’s Health division, to learn how the industry can overcome fu